CR20240015A - COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203) - Google Patents
COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203)Info
- Publication number
- CR20240015A CR20240015A CR20240015A CR20240015A CR20240015A CR 20240015 A CR20240015 A CR 20240015A CR 20240015 A CR20240015 A CR 20240015A CR 20240015 A CR20240015 A CR 20240015A CR 20240015 A CR20240015 A CR 20240015A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pharmaceutical composition
- receptor antagonist
- mineralocorticoid receptor
- auc
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 229940083712 aldosterone antagonist Drugs 0.000 title abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona una composición farmacéutica que comprende un antagonista del receptor de mineralocorticoides y su uso. Cuando la composición farmacéutica se administra por vía oral a un paciente con enfermedad renal crónica que la necesita, el AUC efectivo y seguro varía de 188 ng*h/ml a 3173 ng*h/ml, con una biodisponibilidad del 50% o más en los mamíferos. Cuando la composición farmacéutica se administra por vía oral a una dosis diaria de 0.1 a 1.0 mg para tratar la enfermedad renal crónica, el AUC se controla a un nivel seguro y eficaz.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610849142 | 2016-09-24 | ||
| PCT/CN2017/102969 WO2018054357A1 (zh) | 2016-09-24 | 2017-09-22 | 含盐皮质激素受体拮抗剂的药物组合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240015A true CR20240015A (es) | 2024-04-05 |
Family
ID=61689352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240015A CR20240015A (es) | 2016-09-24 | 2017-09-22 | COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203) |
| CR20190203A CR20190203A (es) | 2016-09-24 | 2017-09-22 | Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190203A CR20190203A (es) | 2016-09-24 | 2017-09-22 | Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11806344B2 (es) |
| EP (1) | EP3517113A4 (es) |
| JP (2) | JP7090599B2 (es) |
| KR (1) | KR102226516B1 (es) |
| CN (1) | CN109069502B (es) |
| AU (1) | AU2017329549B2 (es) |
| BR (1) | BR112019005214A2 (es) |
| CA (1) | CA3037588C (es) |
| CL (1) | CL2019000753A1 (es) |
| CO (1) | CO2019003808A2 (es) |
| CR (2) | CR20240015A (es) |
| CU (1) | CU24569B1 (es) |
| DO (1) | DOP2019000072A (es) |
| EA (1) | EA201990668A1 (es) |
| EC (1) | ECSP19027578A (es) |
| IL (1) | IL265560B (es) |
| MA (1) | MA45202B1 (es) |
| MX (1) | MX391602B (es) |
| MY (1) | MY195054A (es) |
| NZ (1) | NZ751901A (es) |
| PE (1) | PE20190608A1 (es) |
| PH (1) | PH12019500516A1 (es) |
| RU (2) | RU2725153C1 (es) |
| SG (1) | SG10201912389WA (es) |
| TN (1) | TN2019000063A1 (es) |
| TW (2) | TWI780488B (es) |
| UA (1) | UA123464C2 (es) |
| WO (1) | WO2018054357A1 (es) |
| ZA (1) | ZA201901740B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391602B (es) | 2016-09-24 | 2025-03-21 | Novo Nordisk As | Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso |
| CN113425683B (zh) * | 2021-08-19 | 2022-09-20 | 谢彩华 | 一种三氮脒缓释注射剂及其制备方法 |
| CN116492336B (zh) * | 2023-04-04 | 2024-07-05 | 迪沙药业集团有限公司 | 一种坎地沙坦酯药物组合物 |
| CN120168468B (zh) * | 2025-03-05 | 2025-10-17 | 苏州天马医药集团天吉生物制药有限公司 | 一种非奈利酮制剂及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0700395A2 (en) * | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
| PE20091057A1 (es) * | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
| SMT201900650T1 (it) * | 2010-02-25 | 2020-01-14 | Pfizer | Formulazioni di apixaban |
| CN102372710A (zh) | 2010-08-18 | 2012-03-14 | 山东轩竹医药科技有限公司 | 作为盐皮质激素受体拮抗剂的并环类化合物 |
| CA2814371C (en) * | 2010-10-29 | 2019-03-19 | Algiax Pharmaceuticals Gmbh | Use of malononitrilamides in neuropathic pain |
| EP2937348B1 (en) * | 2012-12-22 | 2021-09-08 | Kbp Biosciences Pte. Ltd. | Process for the preparation of a compound used as mineralocorticoid receptor antagonist |
| MX391602B (es) | 2016-09-24 | 2025-03-21 | Novo Nordisk As | Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso |
-
2017
- 2017-09-22 MX MX2019003339A patent/MX391602B/es unknown
- 2017-09-22 KR KR1020197009917A patent/KR102226516B1/ko not_active Expired - Fee Related
- 2017-09-22 SG SG10201912389WA patent/SG10201912389WA/en unknown
- 2017-09-22 AU AU2017329549A patent/AU2017329549B2/en not_active Ceased
- 2017-09-22 EA EA201990668A patent/EA201990668A1/ru unknown
- 2017-09-22 CN CN201780006183.XA patent/CN109069502B/zh active Active
- 2017-09-22 CR CR20240015A patent/CR20240015A/es unknown
- 2017-09-22 EP EP17852425.2A patent/EP3517113A4/en not_active Withdrawn
- 2017-09-22 BR BR112019005214A patent/BR112019005214A2/pt not_active Application Discontinuation
- 2017-09-22 WO PCT/CN2017/102969 patent/WO2018054357A1/zh not_active Ceased
- 2017-09-22 IL IL265560A patent/IL265560B/en unknown
- 2017-09-22 CA CA3037588A patent/CA3037588C/en active Active
- 2017-09-22 RU RU2019110341A patent/RU2725153C1/ru active
- 2017-09-22 RU RU2020120876A patent/RU2750667C2/ru active
- 2017-09-22 NZ NZ751901A patent/NZ751901A/en not_active IP Right Cessation
- 2017-09-22 US US16/068,432 patent/US11806344B2/en active Active
- 2017-09-22 JP JP2019516210A patent/JP7090599B2/ja not_active Expired - Fee Related
- 2017-09-22 CR CR20190203A patent/CR20190203A/es unknown
- 2017-09-22 UA UAA201904176A patent/UA123464C2/uk unknown
- 2017-09-22 MA MA45202A patent/MA45202B1/fr unknown
- 2017-09-22 PE PE2019000668A patent/PE20190608A1/es unknown
- 2017-09-22 MY MYPI2019001497A patent/MY195054A/en unknown
- 2017-09-22 TN TNP/2019/000063A patent/TN2019000063A1/en unknown
- 2017-09-22 CU CU2019000023A patent/CU24569B1/es unknown
- 2017-09-25 TW TW109132042A patent/TWI780488B/zh active
- 2017-09-25 TW TW106132846A patent/TWI715806B/zh not_active IP Right Cessation
-
2019
- 2019-03-11 PH PH12019500516A patent/PH12019500516A1/en unknown
- 2019-03-20 ZA ZA201901740A patent/ZA201901740B/en unknown
- 2019-03-20 DO DO2019000072A patent/DOP2019000072A/es unknown
- 2019-03-22 CL CL2019000753A patent/CL2019000753A1/es unknown
- 2019-04-15 CO CONC2019/0003808A patent/CO2019003808A2/es unknown
- 2019-04-16 EC ECSENADI201927578A patent/ECSP19027578A/es unknown
-
2021
- 2021-12-03 JP JP2021197101A patent/JP2022037044A/ja not_active Withdrawn
-
2023
- 2023-09-26 US US18/372,968 patent/US20240016796A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ780890A (en) | Pharmaceutical compositions comprising meloxicam | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| WO2018005519A3 (en) | Cancer treatment combinations | |
| PH12019500516A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| EA202090542A1 (ru) | Высококонцентрированные лекарственные формы придопидина | |
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| MX2019011620A (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| MY206893A (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| EP4410295A3 (en) | Use of vibegron to treat overactive bladder | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| JP2016505050A5 (es) | ||
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| PH12018500889A1 (en) | Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine | |
| EP4052699A4 (en) | MEDICINE IN SOLID PHARMACEUTICAL FORM ADMINISTERED ORALLY | |
| TW201613606A (en) | Therapeutic drug for chronic renal failure | |
| RU2023102211A (ru) | Схемы дозирования иммуноконъюгата anti-folr1 | |
| WO2016187595A3 (en) | Oral pharmaceutical composition of methylergonovine | |
| TH1901001650A (th) | องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยมิเนอรัลโลคอร์ติคอยด์รีเซ็ปเตอร์แอนตาโกนิสต์และการใช้สารดังกล่าว | |
| HRP20230105T1 (hr) | N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti | |
| WO2016193456A3 (en) | Opioid receptor antagonist for use in treating patients with severe constipation | |
| EA201691599A1 (ru) | Комбинация таурина и рацеметионина для лечения заболеваний печени |